Acid-fast bacilli

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Monday, August 2, 2021
Medical specialties, Microbiology, Infectious diseases, Acid-fast bacilli, Bacterial diseases, Bacteriology, Infectious causes of cancer, Healthcare-associated infections, Nontuberculous mycobacteria, Omadacycline, Mycobacterium, Tuberculosis

These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.

Key Points: 
  • These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.
  • Paratek has a collaboration agreement withZaiLab for the development and commercialization of omadacycline in the greaterChinaregion and retains all remaining global rights.
  • Paratek is also conducting a Phase 2b Study in a rare disease, Nontuberculous Mycobacterial (NTM) Pulmonary Disease, caused by Mycobacterium abscessus Complex (MABc) with NUZYRA.
  • Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

Paratek Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 9, 2021

Retrieved on: 
Monday, August 2, 2021
Medical specialties, Microbiology, Infectious diseases, Acid-fast bacilli, Bacterial diseases, Bacteriology, Infectious causes of cancer, Healthcare-associated infections, Nontuberculous mycobacteria, Mycobacterium, Omadacycline, Tuberculosis

Domestic investors wishing to participate in the call should dial: 855-327-6837 and international investors should dial: 631-891-4304.

Key Points: 
  • Domestic investors wishing to participate in the call should dial: 855-327-6837 and international investors should dial: 631-891-4304.
  • Paratek Pharmaceuticals, Inc.is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government andmilitary use.
  • Paratek has a collaboration agreement withZaiLab for the development and commercialization of omadacycline in the greaterChinaregion and retains all remaining global rights.
  • Paratek is also conducting a Phase 2b Study in a rare disease, Nontuberculous Mycobacterial (NTM) Pulmonary Disease, caused by Mycobacterium abscessus Complex (MABc) with NUZYRA.

Praedicare Inc. Receives Grant to Evaluate Potential New Drug Regimens for Tuberculosis

Retrieved on: 
Thursday, June 17, 2021
Biotechnology, General Health, Hospitals, Health, Pharmaceutical, Medical specialties, Tuberculosis, Infectious diseases, Microbiology, Infectious causes of cancer, Acid-fast bacilli, Pathogenic bacteria, Health in Africa, Mycobacterium tuberculosis, Mycobacterium, Drug development

Praedicare Inc., a CRO using unique pre-clinical laboratory and proprietary mathematical translation models today announced it has been awarded a two-year, $2.8 million grant by the Bill & Melinda Gates Foundation to evaluate novel TB drug regimens using Praedicares in vitro hollow fiber model of Tuberculosis (TB) in identifying potential new drug regimens that shorten treatment times for the disease.

Key Points: 
  • Praedicare Inc., a CRO using unique pre-clinical laboratory and proprietary mathematical translation models today announced it has been awarded a two-year, $2.8 million grant by the Bill & Melinda Gates Foundation to evaluate novel TB drug regimens using Praedicares in vitro hollow fiber model of Tuberculosis (TB) in identifying potential new drug regimens that shorten treatment times for the disease.
  • The study will also include pharmacokinetic and pharmacodynamic evaluation of the drugs.
  • TB is caused by Mycobacterium tuberculosis that most often affects the lungs.
  • Praedicare Inc. is an end-to-end drug development company, from drug discovery, through preclinical work, to phase IV clinical trials.

Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc) with NUZYRA® (omadacycline)

Retrieved on: 
Wednesday, June 16, 2021
Acid-fast bacilli, Mycobacterium abscessus, Health, Medical specialties, Microbiology, Lung disorders, Nontuberculous mycobacteria

Pulmonary infections caused by MABc, an orphan disease with no FDA-approved antibiotic therapies, affects approximately 11,500 patients in the U.S.

Key Points: 
  • Pulmonary infections caused by MABc, an orphan disease with no FDA-approved antibiotic therapies, affects approximately 11,500 patients in the U.S.
  • Patients with pulmonary disease caused by M. abscessus have a myriad of symptoms including severe fatigue, fever, cough and shortness of breath.
  • The Phase 2b study is a placebo-controlled, randomized monotherapy study of M. abscessus pulmonary disease in patients in the early treatment phase who are not receiving other treatments.
  • Due to the small numbers of patients with this rare disease, Paratek expects the study will take about two years to complete enrollment.

World Gastroenterology Organisation (WGO) Announces the Release of the New Digestive Tract Tuberculosis Guideline

Retrieved on: 
Tuesday, April 27, 2021
Medical specialties, Microbiology, Tuberculosis, Clinical medicine, Infectious causes of cancer, Acid-fast bacilli, Pathogenic bacteria, World Gastroenterology Organisation, WGO, Bacteriology, Mycobacterium, TB

b'MILWAUKEE, April 27, 2021 /PRNewswire-PRWeb/ --The World Gastroenterology Organisation (WGO) has announced the release of the new Digestive Tract Tuberculosis Guideline.

Key Points: 
  • b'MILWAUKEE, April 27, 2021 /PRNewswire-PRWeb/ --The World Gastroenterology Organisation (WGO) has announced the release of the new Digestive Tract Tuberculosis Guideline.
  • This Guideline is chaired by Mohamed Tahiri of the IBN Rochd University Hospital in Casablanca, Morocco and K.L.
  • The Guideline can be accessed here .\nIn introducing this Guideline, Prof. Tahiri stated, "Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis, typically causing pulmonary TB.
  • For more information, contact: [email protected] .\nWGO Secretariat, World Gastroenterology Organisation (WGO), +1 (414) 918-9798, [email protected]\n'

Beyond Air® to Present Abstracts at the American Thoracic Society Virtual Sessions in May 2021

Retrieved on: 
Wednesday, March 24, 2021
Medical specialties, Branches of biology, Microbiology, Bacterial diseases, Bacteriology, Infectious causes of cancer, Acid-fast bacilli, Nontuberculous mycobacteria, Tuberculosis, Lung, NTM, Respiratory tract

Beyond Air is currently advancing its revolutionary LungFit for clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM).

Key Points: 
  • Beyond Air is currently advancing its revolutionary LungFit for clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM).
  • Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting.
  • In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs.
  • Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made.

Nontuberculous Mycobacteria Isolated from Environmental Water Samples with New Culture Media

Retrieved on: 
Friday, March 5, 2021
Microbiology, Acid-fast bacilli, Branches of biology, Middlebrook 7H10 Agar, Decontamination, Nontuberculous mycobacteria

The study, Evaluation of a new culture medium for isolation of Nontuberculous mycobacteria from environmental water samples ( https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0247166 ), published in PLOS ONE, examines the efficacy of the new RGM media.

Key Points: 
  • The study, Evaluation of a new culture medium for isolation of Nontuberculous mycobacteria from environmental water samples ( https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0247166 ), published in PLOS ONE, examines the efficacy of the new RGM media.
  • This new media formulation requires no chemical decontamination process, controls mold and bacterial overgrowth, and is a much faster process than other methods.
  • To analyze the effectiveness of RGM in environmental water samples, microbiologists analyzed 233 water samples from different facilities across the United States.
  • Samples were placed on three different types of culture media: 1) standard acid decontamination followed by culture on Middlebrook 7H10 medium; 2) Standard acid decontamination followed by culture on Mitchison 7H11 medium; 3) Culture on RGM without acid decontamination.

Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in March 2021

Retrieved on: 
Monday, March 1, 2021
Medical specialties, Microbiology, Clinical medicine, Bacterial diseases, Bacteriology, Infectious causes of cancer, Acid-fast bacilli, Nontuberculous mycobacteria, Tuberculosis, NTM, Mycobacterium, Severe acute respiratory syndrome

Virtual presentation is scheduled for Tuesday, March 16th at 9:20 AM ET

Key Points: 
  • Virtual presentation is scheduled for Tuesday, March 16th at 9:20 AM ET
    Please contact your representative at either Roth or Oppenheimer to schedule a virtual one-on-one meeting with Beyond Air during the respective conference.
  • Beyond Air is currently advancing its revolutionary LungFit for clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM).
  • Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting.
  • Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made.

Spero Therapeutics to Present at Investor Conferences in March

Retrieved on: 
Thursday, February 25, 2021
Medical specialties, Microbiology, Bacterial diseases, Bacteriology, Infectious causes of cancer, Tuberculosis, Acid-fast bacilli, Nontuberculous mycobacteria, Multiple drug resistance, Mycobacterium

Replays of corporate presentations will be archived on the website for 90 days following the conclusion of each event.

Key Points: 
  • Replays of corporate presentations will be archived on the website for 90 days following the conclusion of each event.
  • Spero Therapeutics, Inc.is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
  • InSeptember 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.
  • Spero is also developing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.

Beyond Air® Schedules Third Fiscal Quarter 2021 Financial Results Conference Call and Webcast

Retrieved on: 
Friday, January 15, 2021
Medical specialties, Microbiology, Sarbecovirus, Infectious diseases, Bacterial diseases, Bacteriology, Infectious causes of cancer, Acid-fast bacilli, Nontuberculous mycobacteria, Forward-looking statement, NTM, Tuberculosis

Beyond Air is currently advancing its revolutionary LungFit for clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM).

Key Points: 
  • Beyond Air is currently advancing its revolutionary LungFit for clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM).
  • Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting.
  • Forward-looking statements include statements about our expectations, beliefs, or intentions regarding our product offerings, business, financial condition, results of operations, strategies or prospects.
  • Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made.